Abstract Progressive supranuclear palsy is a rare and rapidly progressive neurodegenerative syndrome. Clinical manifestations are heterogeneous and include Parkinsonism, postural instability, oculomotor dysfunction and cognitive impairment, with 80% of patients progressing to dementia within 3 years. Cognitive impairme...
Timothy P. Siejka, K. Bertram, H. Butzkueven et al.· Movement Disorders Clinical...· 0 citations
Findings identify a reproducible X-chromosome hypomethylation signature in female MS and support direct investigation of inactive-X regulation, XCI escape and X-linked immune gene dosage.
T. Calnin, V. Maltby, S. Burnard et al.· medRxiv· 0 citations
BACKGROUND
Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice.
METHODS
We conducted an observational cohort study emulating...
Chao Zhu, S. Vukusic, T. Kalincik et al.· Journal of Neurology Neurosu...· 0 citations
In this longitudinal study, mean sGFAP and sNfL levels remained stable over 9 years of sequential measurements during relapse-free periods, supporting the relapse-driven nature of NMOSD pathology.
P. Siriratnam, C. Dunai, Nkongho Egbe Franklyn et al.· Journal of Neurology Neurosu...· 0 citations
Key updates include expansion of dissemination in space to incorporate the optic nerve, integration of relapsing and progressive onset MS within a unified diagnostic framework, provision for diagnosis in selected asymptomatic individuals, dispensing with the requirement for dissemination of time in certain situations a...
P. Siriratnam, Mineesh Datta, Katherine A. Buzzard et al.· Autoimmunity Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
